Search results

Back
1 - 10 of 34 Search results
    - 

 - 

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

PARIS, FRANCE, 10 June 2024  Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis ...


    - 

 - 

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

PARIS, FRANCE, 13 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorour...


    - 

 - 

Module 1 – banner_NEUROSCIENCE_ipsen-33

...


    - 

 - 

Module 2 – Brief about neuroscience_IPSEN_Production_Signes_060

...


    - 

 - 

Module 2 – Brief about neuroscience_IPSEN_Production_Signes_060

...



    - 

 - 

Module 8 – Neuroscience pipeline_191209_0729

...


    - 

 - 

Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy

– In PRESTO, almost all nurse participants (97.8%) reported a preference* for the Somatuline® Depot(lanreotide) redesigned pre-filled syringe compared with the syringe for long-acting release octreotide–CAMBRIDGE, Mass. March 11, 2020 — Ipsen Biopha...


    - 

 - 

Neuroscience RFP 2024

...


    - 

 - 

Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma

PARIS, FRANCE, 9 November 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced the Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint d...


1 2 3 4